Sacituzumab govitecan - Immunomedics

Drug Profile

Sacituzumab govitecan - Immunomedics

Alternative Names: hRS7-SN38 antibody drug conjugate; IMMU-132; Isactuzumab govitecan; TROP-2-SN-38

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators; TROP2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Solid tumours
  • Preclinical Pancreatic cancer
  • No development reported Small cell lung cancer

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA
  • 11 Jan 2018 Immunomedics enters into an agreement with the University of Wisconsin for a phase II trial of Sacituzumab govitecan
  • 11 Jan 2018 Imunomedics plans a phase II trial for Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top